Skip to main content
Premium Trial:

Request an Annual Quote

Bill Summers, Justin Stephenson, Joel Bellenson, Susan Lowther


Thermo Electron has hired Bill Summers as global sales director of informatics, a newly created position. Summers comes to Thermo from Aspen Technology, where he was most recently vice president of sales for chemicals/pharmaceuticals.

Kinexus Bioinformatics has appointed Justin Stephenson and Joel Bellenson to its board of directors. Stephenson is the founder and president of Galiano Ventures, a Vancouver-based venture capital firm specializing in the life sciences industries. Bellenson is currently the president and CEO of Upstream Biosciences, a Vancouver-based company developing software for modeling cell systems, protein signaling, and gene regulatory pathways. Bellenson was the co-founder and CEO of DigiScents and the co-founder, CEO, chief strategist, and director of DoubleTwist.

BioWisdom has appointed Susan Lowther as its chief financial officer. Lowther most recently worked as a consultant to early-stage venture capital-backed companies. She previously served as finance director of RiboTargets until its merger with British Biotech in 2003. Lowther has also held senior financial management positions at Lonza Biologics, Celltech Group, and GD Searle (a division of Monsanto).

Filed under

The Scan

Fertility Fraud Found

Consumer genetic testing has uncovered cases of fertility fraud that are leading to lawsuits, according to USA Today.

Ties Between Vigorous Exercise, ALS in Genetically At-Risk People

Regular strenuous exercise could contribute to motor neuron disease development among those already at genetic risk, Sky News reports.

Test Warning

The Guardian writes that the US regulators have warned against using a rapid COVID-19 test that is a key part of mass testing in the UK.

Science Papers Examine Feedback Mechanism Affecting Xist, Continuous Health Monitoring for Precision Medicine

In Science this week: analysis of cis confinement of the X-inactive specific transcript, and more.